Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance.

Item

http://www.wikidata.org/entity/Q40728808

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Novel Cytomegalovirus UL54 DNA ...... nfer Brincidofovir Resistance.

@en

type

Item

label

Novel Cytomegalovirus UL54 DNA ...... nfer Brincidofovir Resistance.

@en

prefLabel

Novel Cytomegalovirus UL54 DNA ...... nfer Brincidofovir Resistance.

@en

P1476

Novel Cytomegalovirus UL54 DNA ...... nfer Brincidofovir Resistance.

@en

P2093

E Randall Lanier

http://www.w3.org/2001/XMLSchema#string

Ronald J Ercolani

http://www.w3.org/2001/XMLSchema#string

Sunwen Chou

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of ganciclovir-induced chain termination revealed by resistant viral polymerase mutants with reduced exonuclease activity

Antiviral drug resistance of human cytomegalovirus.

Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.

First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses.

Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.

Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.

Utility of the bacteriophage RB69 polymerase gp43 as a surrogate enzyme for herpesvirus orthologs.

Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways.

Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet.

Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis.

P304

3845-3848

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00214-16

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27044553

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus

P932

4879386

http://www.w3.org/2001/XMLSchema#string